Tin tức & Cập nhật
Lọc theo Chuyên ngành:

Tislelizumab a new Tx alternative for very high-risk bladder cancer?
06 Mar 2025
bởiAudrey Abella
In the phase II pilot TRUCE-02 trial, tislelizumab plus low-dose nab-paclitaxel shows promising clinical antitumour activity and is well tolerated in patients with extensive very high-risk (VHR) non-muscle-invasive bladder cancer (NMIBC) who are ineligible for or decline radical cystectomy (RC).